SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell r variants and HCoV-NL63

Journal of Clinical Investigation

131,

DOI: 10.1172/jci149335

Citation Report

#	Article	IF	Citations
2	Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. International Journal of Infectious Diseases, 2021, 106, 429-430.	3.3	4
6	Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. Clinical and Experimental Immunology, 2021, 205, 363-378.	2.6	34
7	How long does covid-19 immunity last?. BMJ, The, 2021, 373, n1605.	6.0	36
8	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. Clinical Infectious Diseases, 2021, 73, 2000-2008.	5.8	30
11	Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€CoVâ€2 variants of concern: A systematic review of in vitro studies. Reviews in Medical Virology, 2022, 32, e2277.	8.3	57
13	Human Coronaviruses: Counteracting the Damage by Storm. Viruses, 2021, 13, 1457.	3.3	5
14	The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2022, 74, 1268-1270.	5.8	118
18	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Immunologic Research, 2021, 69, 576-583.	2.9	34
21	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines, 2021, 9, 1163.	3.2	18
23	Rapid growth in the COVID-19 era. MRS Bulletin, 2021, 46, 847-853.	3.5	3
24	Rapid induction of antigen-specific CD4+ TÂcells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity, 2021, 54, 2133-2142.e3.	14.3	367
25	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	8.2	89
26	SARS-CoV-2-specific T cells in infection and vaccination. Cellular and Molecular Immunology, 2021, 18, 2307-2312.	10.5	131
27	Evaluation of the QuantiFERON SARS-CoV-2 interferon-É£ release assay in mRNA-1273 vaccinated health care workers. Journal of Virological Methods, 2021, 298, 114295.	2.1	37
28	Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects?. Drug Discoveries and Therapeutics, 2021, 15, 278-280.	1.5	10
29	Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. BMC Clinical Pathology, 2021, 14, 2632010X2110492.	1.7	9
30	mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€“Specific T Cells Persist at 6 Months and Recognize the Delta Variant. Clinical Infectious Diseases, 2022, 75, e898-e901.	5.8	25
31	Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272. International Journal of Infectious Diseases, 2021, 113, 125-126.	3.3	13

#	Article	IF	Citations
32	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. ELife, 2021, 10, .	6.0	63
33	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
35	Response to Mishra et al. re â€œPostinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2â€. Viral Immunology, 2021, 34, 659-660.	1.3	0
36	Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine, 2021, 73, 103636.	6.1	85
37	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.8	4
38	BNT162b2 vaccination induces durable SARS-CoV-2â€“specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eabl5344.	11.9	166
39	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	4.4	22
40	Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2. Journal of Personalized Medicine, 2021, 11, 1253.	2.5	3
41	Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?. Frontiers in Medicine, 2021, 8, 770381.	2.6	14
42	Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial. SSRN Electronic Journal, 0, , .	0.4	1
43	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. Journal of Autoimmunity, 2022, 127, 102792.	6.5	96
44	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. European Journal of Cancer, 2022, 162, 182-193.	2.8	40
46	CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses. Journal of Clinical Investigation, 2022, 132, .	8.2	16
48	TNFÎ±-Producing CD4 ⁺ T Cells Dominate the SARS-CoV-2-Specific T Cell Response in COVID-19 Outpatients and Are Associated with Durable Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
50	Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2. Frontiers in Immunology, 2021, 12, 812176.	4.8	10
51	The T cell immune response against SARS-CoV-2. Nature Immunology, 2022, 23, 186-193.	14.5	785
52	Accuracy and real life performance of a novel interferon-Î³ release assay for the detection of SARS-CoV2 specific T cell response. Journal of Clinical Virology, 2022, 148, 105098.	3.1	24
53	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	5.0	12

#	Article	IF	Citations
54	Peculiarities of the T Cell Immune Response in COVID-19. Vaccines, 2022, 10, 242.	4.4	24
55	The germinal centre B cell response to SARS-CoV-2. Nature Reviews Immunology, 2022, 22, 7-18.	22.7	150
58	The Journal of Clinical Investigation in the time of COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	2
59	Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers. Clinical and Experimental Vaccine Research, 2022, 11, 96.	2.2	3
60	Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nature Communications, 2022, 13, 864.	12.8	72
61	Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19. Frontiers in Immunology, 2021, 12, 804808.	4.8	7
62	Comparison of Seroconversion in Children and Adults With Mild COVID-19. JAMA Network Open, 2022, 5, e221313.	5.9	55
63	Cellular Immunityâ€"The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. Vaccines, 2022, 10, 442.	4.4	21
64	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ, 2022, 10, e13083.	2.0	14
65	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. Journal of Infectious Diseases, 2022, 226, 1372-1381.	4.0	41
66	Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine. Frontiers in Immunology, 2022, 13, 786586.	4.8	13
67	Rituximabâ€treated patients with lymphoma develop strong <scp>CD8</scp> Tâ€cell responses following <scp>COVID</scp>â€19 vaccination. British Journal of Haematology, 2022, 197, 697-708.	2.5	22
68	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nature Immunology, 2022, 23, 768-780.	14.5	41
69	Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 ⁺ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. MBio, 2022, 13, e0361721.	4.1	67
70	Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis, 2022, 16, 1347-1353.	1.3	8
71	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine, 2022, 77, 103904.	6.1	93
72	In the shadow of antibodies: how T cells defend against COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 757-759.	0.9	2
73	SARS-CoV-2â€"specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. JCI Insight, 2022, 7, .	5.0	15

#	Article	IF	Citations
74	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. Journal of Clinical Virology, 2022, 150-151, 105151.	3.1	11
75	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals. PLoS Pathogens, 2021, 17, e1010203.	4.7	24
76	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. Cells, 2022, 11, 67.	4.1	7
78	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 978-985.	1.9	17
79	Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients. Clinical Infectious Diseases, 2022, 75, 1652-1654.	5.8	4
80	TNF-Î±+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	6.5	15
81	Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Review of Clinical Immunology, 2022, 18, 557-565.	3.0	10
82	Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	4.8	39
83	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. Journal of Infectious Diseases, 2022, 226, 1731-1742.	4.0	8
84	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. EBioMedicine, 2022, 80, 104048.	6.1	12
85	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. Nature Microbiology, 2022, 7, 909-917.	13.3	41
86	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients â€“ implications for the omicron variant. Journal of Heart and Lung Transplantation, 2022, 41, 1417-1425.	0.6	10
87	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	4.8	7
88	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	2.8	24
89	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
90	Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. Journal of Virology, 2022, 96, .	3.4	19
91	Comment on â€œMultibacillary leprosy unmasked by COVID-19 vaccinationâ€• JAAD Case Reports, 2022, 26, 1-2.	0.8	0
92	Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood. ImmunoHorizons, 2022, 6, 398-407.	1.8	0

#	Article	IF	Citations
93	Immunological memory to <scp>SARSâ€CoV</scp>â€2 infection and <scp>COVID</scp>â€19 vaccines. Immunological Reviews, 2022, 310, 27-46.	6.0	137
94	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nature Communications, 2022, 13, .	12.8	28
95	Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications. Journal of Clinical Practice, 2022, 13, 66-87.	0.6	1
96	Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery. Immuno-Oncology Technology, 2022, 16, 100091.	0.3	4
97	Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot. Heliyon, 2022, 8, e09863.	3.2	5
98	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. Frontiers in Immunology, 0, 13, .	4.8	4
99	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. Frontiers in Immunology, 0, 13, .	4.8	2
100	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	4.8	13
101	Immunogenicity of <scp>COVID</scp>â€19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and metaâ€analysis. Liver International, 2023, 43, 34-48.	3.9	14
102	SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology, 2022, 3, .	2.8	12
104	T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 1494.	4.4	6
105	SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Nature Communications, 2022, 13, .	12.8	37
106	Development of SARSâ€CoVâ€2 animal vaccines using a stable and efficient NDV expression system. Journal of Medical Virology, 2023, 95, .	5.0	2
107	Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines. Frontiers in Immunology, 0, 13, .	4.8	12
108	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
109	Keeping T cell memories in mind. Trends in Immunology, 2022, 43, 1018-1031.	6.8	3
110	Seasonal respiratory virus circulation was diminished during the COVIDâ€19 pandemic. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	4
111	A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. Virus Research, 2023, 324, 199024.	2.2	5

#	Article	IF	Citations
112	In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19. Covid, 2022, 2, 1731-1747.	1.5	1
113	Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory. Scientific Reports, 2022, 12, .	3.3	1
114	Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH. International Journal of Molecular Sciences, 2022, 23, 14988.	4.1	8
115	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	3.8	2
116	Factors Associated With Vaccine-Induced T-Cell Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Kidney Transplant Recipients. Journal of Infectious Diseases, 0, , .	4.0	4
117	Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations. Annals of Laboratory Medicine, 2023, 43, 290-294.	2.5	1
118	Multipolymer microsphere delivery of SARS-CoV-2 antigens. Acta Biomaterialia, 2023, 158, 493-509.	8.3	4
120	Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations. Vaccine: X, 2022, 12, 100246.	2.1	3
121	A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19. Molecular Therapy, 2023, 31, 788-800.	8.2	8
122	Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	7
123	Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Frontiers in Immunology, 0, 14, .	4.8	5
124	Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. International Journal of Molecular Sciences, 2023, 24, 6731.	4.1	5
125	T Cell Responses to SARS-CoV-2. Annual Review of Immunology, 2023, 41, 343-373.	21.8	48
126	mRNA vaccines: The future of prevention of viral infections?. Journal of Medical Virology, 2023, 95, .	5.0	24
128	A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern. Microbiology Spectrum, 2023, 11, .	3.0	1
130	mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic. Frontiers in Immunology, 0, 14, .	4.8	3
131	Bivalent COVID-19 Vaccines: Can the Original Antigenic Sin Be Forgiven?. Journal of Infectious Diseases, 2023, 227, 1221-1223.	4.0	2
132	Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination. Clinical Immunology, 2023, 251, 109342.	3.2	0

#	Article	IF	Citations
133	Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. The Lancet Healthy Longevity, 2023, 4, e188-e199.	4.6	5
134	Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2. Rheumatology, 2024, 63, 534-541.	1.9	1
135	Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. Journal of Immunology, 2023, 211, 351-364.	0.8	8
136	Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers. Journal of Clinical Medicine, 2023, 12, 3172.	2.4	1
137	SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Frontiers in Immunology, 0, 14, .	4.8	1
138	Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults. Frontiers in Immunology, 0, 14, .	4.8	0
139	Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2. PLoS Pathogens, 2023, 19, e1011032.	4.7	1
140	A unique cytotoxic CD4⁺ T cellâ€signature defines critical COVIDâ€19. Clinical and Translational Immunology, 2023, 12, .	3.8	0
141	Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus. Viruses, 2023, 15, 1844.	3.3	0
142	A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2023, 24, 14223.	4.1	0
143	T cell responses to SARS-COV-2. Progress in Molecular Biology and Translational Science, 2023, , .	1.7	0
144	Insights into the T-cell response to SARS-CoV-2. European Journal of Inflammation, 2023, 21, .	0.5	0
145	A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation. Npj Vaccines, 2024, 9, .	6.0	0
146	People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination. Frontiers in Immunology, 0, 14, .	4.8	0
148	Omicron BA.2 breakthrough infection elicits CD8 ⁺ T cell responses recognizing the spike of later Omicron subvariants. Science Immunology, 2024, 9, .	11.9	1
149	Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients. Vaccines, 2024, 12, 174.	4.4	0
150	Omicron BA.4/5 neutralization and cellâ€mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A followâ€up cohort study. Journal of Medical Virology, 2024, 96, .	5.0	0
151	Current Understanding of the Immune Response after COVID-19 Vaccination. Vaccines, 2024, 12, 250.	4.4	0

#	Article	IF	Citations
152	Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ TÂcell clonotypes. Cell Reports Medicine, 2024, 5, 101442.	6.5	0
153	The Influence of Cross-Reactive T Cells in COVID-19. Biomedicines, 2024, 12, 564.	3.2	0
154	A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against Î²-Coronaviruses in a Murine Model. Viruses, 2024, 16, 484.	3.3	0